Technical Analysis for LXRX - Lexicon Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 5.37% | |
| NR7-2 | Range Contraction | 5.37% | |
| Narrow Range Bar | Range Contraction | 5.37% | |
| Wide Bands | Range Expansion | 5.37% | |
| NR7 | Range Contraction | 5.37% | |
| Wide Bands | Range Expansion | 5.37% | |
| Crossed Above 20 DMA | Bullish | 1.91% | |
| Inside Day | Range Contraction | 1.91% | |
| Wide Bands | Range Expansion | 1.91% | |
| Up 3 Days in a Row | Strength | 1.91% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 4 hours ago |
| Rose Above Previous Day's High | about 4 hours ago |
| Up 5% | about 4 hours ago |
| Up 3% | about 4 hours ago |
| Up 2% | about 5 hours ago |
Get a Trading Assistant
- Earnings date: 04/30/2024
Lexicon Pharmaceuticals, Inc. Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for human disease. Its portfolio of orally-delivered small molecule compounds in clinical development include LX4211 that has completed two Phase II clinical trials for the treatment of type 1 and type 2 diabetes; LX1032, which is in Phase III clinical trials for the treatment of carcinoid syndrome and ulcerative colitis; and LX1033 that is in Phase II clinical trials for the treatment of irritable bowel syndrome. The company is also developing LX2931 that has completed Phase II clinical trials for the treatment of rheumatoid arthritis; and LX7101, which is in Phase I clinical trials for the treatment of glaucoma. It has drug discovery and development collaborations with Bristol-Myers Squibb Company; Genentech, Inc.; Schering-Plough/Organon; and Takeda Pharmaceutical Company Limited. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Clinical Development Diabetes Monoclonal Antibodies Drug Discovery Clinical Trial Rheumatoid Arthritis Ulcerative Colitis Human Diseases Glaucoma Ulcer Colitis Irritable Bowel Syndrome Treatment Of Glaucoma Biotie Therapies
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.73 |
| 52 Week Low | 0.9201 |
| Average Volume | 3,919,813 |
| 200-Day Moving Average | 1.67 |
| 50-Day Moving Average | 2.06 |
| 20-Day Moving Average | 1.70 |
| 10-Day Moving Average | 1.67 |
| Average True Range | 0.15 |
| RSI (14) | 47.09 |
| ADX | 17.69 |
| +DI | 28.85 |
| -DI | 17.52 |
| Chandelier Exit (Long, 3 ATRs) | 1.71 |
| Chandelier Exit (Short, 3 ATRs) | 1.94 |
| Upper Bollinger Bands | 1.97 |
| Lower Bollinger Band | 1.44 |
| Percent B (%b) | 0.62 |
| BandWidth | 31.44 |
| MACD Line | -0.09 |
| MACD Signal Line | -0.13 |
| MACD Histogram | 0.0419 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.88 | ||||
| Resistance 3 (R3) | 1.88 | 1.85 | 1.86 | ||
| Resistance 2 (R2) | 1.85 | 1.82 | 1.85 | 1.85 | |
| Resistance 1 (R1) | 1.81 | 1.81 | 1.80 | 1.81 | 1.85 |
| Pivot Point | 1.78 | 1.78 | 1.77 | 1.78 | 1.78 |
| Support 1 (S1) | 1.74 | 1.75 | 1.73 | 1.74 | 1.69 |
| Support 2 (S2) | 1.71 | 1.74 | 1.71 | 1.69 | |
| Support 3 (S3) | 1.67 | 1.71 | 1.68 | ||
| Support 4 (S4) | 1.67 |
